mylan afterthought merger underdog asset
updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim aug
price data aug
rate updat aug
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
foundat remain solid base strong cash flow
gener basket divers drug compani larg size
confer signific competit advantag develop new
drug unmatch heft combin broad portfolio
patent-protect drug help build wide econom
moat around busi
size establish one largest economi scale
pharmaceut industri busi drug develop
need lot shot goal success financi
resourc establish research power support
develop new drug also mani year
struggl bring import new drug launch
sever potenti blockbust cancer heart diseas
commit postapprov studi provid
salespeopl armamentarium data market
campaign lead salesforc emerg
countri posit compani benefit dramat
increas wealth nation brazil russia india china
turkey
entrench industri leader face challeng
near term loss patent protect sever drug
weigh futur growth particular recent patent loss
viagra eventu patent loss lyrica
slow long-term growth
howev believ oper withstand
upcom gener competit acquisit wyeth
help insul one particular patent loss follow
merger much stronger posit vaccin
industri pneumococc vaccin prevnar vaccin tend
resist gener competit
manufactur complex rel lower price
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net earn share outstand
one world largest pharmaceut firm annual sale
billion also spend lead amount research
develop close billion annual histor sold mani
type healthcar product chemic prescript drug
vaccin account major sale top seller includ pneumococc
cardiovascular treatment eliqui immunolog drug enbrel xeljanz
sell product global intern sale repres
close total sale within intern sale emerg market
major contributor repres fifth total compani sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mylan afterthought merger underdog asset
normal ep came notabl expect
result secondari announc tax-fre
divestitur combin off-pat
brand gener busi upjohn new entiti
largest gener manufactur signific scale
result better-than-expect quarterli oper
margin ramp fulphila oncolog wixela
asthma increas full-year non-gaap ep
although second-quart estim
short see signific upsid fair
valu estim current oper margin like
sustain base compani stand-alon
exist pipelin share intra-day
trade near fair valu maintain no-moat rate
await addit transact detail
combin two gener busi provid mylan
sharehold ownership new compani
new entiti would displac teva largest gener drug
manufactur compani focus develop complex
gener purpos de-emphasize north american
gener market duress view
stand-alon busi like weakest
competitor highli competit market
combin logic step would provid better
foot market scale critic differenti
departur key execut hope
includ roughli million synergi roughli
billion synergi seem conserv
consid teva track reduc billion oper
expens stand-alon basi manag target
debt/adjust ebitda ratio
stand-alon plan initi dividend
least free cash flow first quarter
increas fair valu estim per share
basi higher project rare-diseas
drug tafamidi look increasingli well posit
breakthrough statu grant
cardiomyopathi diseas associ progress
heart failur phase data drug drive
approv lead billion annual peak sale
look core busi expect annual
sale growth next three year
acquisit new drug off-set gener competit
howev bottom line project slightli healthier
annual growth rate next three year
cost-cut plan share buyback take shape
model unannounc acquisit acquisit hold
potenti acceler compani growth rate
long term believ diversifi line-up drug
reduc volatil earn anticip
restructur effort elimin duplic
posit help allevi margin pressur
high-margin product lose exclus cost capit
perspect estim cost equiti
weight averag cost capit line peer
larg base low volatil cash flow
divers product portfolio inelast demand rate
uncertainti low scenario analysi assum
base-cas fair valu estim bull-cas fair
valu estim probabl bear case
probabl project fair valu rel
base case scenario analysi show minor varianc
henc low uncertainti rate key factor affect
scenario analysi includ degre success
brand drug pipelin along magnitud market
pressur current market drug within group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
line creat enorm cash flow need fund
averag million develop cost per new drug
addit compani power distribut network
set compani strong partner smaller drug
compani lack resourc entrench
consum vaccin franchis creat ad layer
competit advantag stem brand power
consum healthcar manufactur cost advantag
vaccin divis consid sell
consum healthcar group potenti divest
materi impact compani moat
believ face stabl moat trend next
five year compani major patent loss repres
total sale howev strong pipelin
combin stabl current market drug lead
modest growth annual period
exclud acquisit also patent exposur
face biolog shouldnt declin fast
small molecul patent expir offset
patent loss pipelin side expect
billion peak annual sale three new drug includ
recent launch ibranc cancer pipelin drug
tanezumab pain ertugliflozin diabet
turn macroeconom environ
sever headwind make solid strateg move
address challeng neg side
risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
organ pharmaci benefit manag
consolid past decad use
grow size demand lower drug price reduc
coverag less innov drug forc drug firm
push true innov reduc power pfizer
distribut network govern
recent launch drug import driver
valuat ibranc cancer addit unknown
magnitud biosimilar competit
immunolog diseas weigh certainti
enbrel
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
competit aris addit hold
diversifi product portfolio
product
concentr compani largest product prevnar
repres total sale howev
expect typic gener competit vaccin due
complex manufactur rel low price
product expect new product mitig
eventu gener competit key drug also
pfizer oper structur allow cost-cut follow
patent loss reduc margin pressur lost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
evalu compar effect program
aggress price negoti rais bar futur
innov face sever headwind
pipelin focus innov treatment area
unmet medic area cancer payer
coverag price power remain strong outsid
pipelin compani strong entrench vaccin
consum healthcar give firm relief
pressur drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pipelin product improv sever
potenti game-chang immunolog
major
blockbust breast cancer
ibranc develop
oth stock support dividend yield
expect steadi cash flow support dividend
owhil decid break compani
innov core establish drug group
increas visibl segment option
revisit decis creat potenti futur valu
research
late-stag pipelin look strong enough
drive robust growth
oalthough compani worst
patent cliff still face recent major patent loss
viagra futur one lyrica
osever late-stag pipelin drug
enter crowd market may limit share gain
due delay entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
hold strong financi posit larg
degre flexibl end debt/capit
stood debt/ebitda ratio
suggest remain solid financi foot
major cash flow deriv divers portfolio
product dont expect high degre volatil
futur earn like continu make
acquisit believ rel easili take debt
fund larger deal
face gener competit increasingli stringent
fda stronger managed-car pharmaci benefit
manag negoti power new drug develop
becom challeng sever diseas area
pharmaci benefit manag grown past
two decad power entiti negoti lower
drug price although remot litig risk remain
evidenc merck high settlement cost involv
vioxx also sever pipelin drug reach
market behind competitor may increas risk
commerci failur put downward price
pressur drug clinic data lack posit
differenti brand competit front merck
work develop next-gener pneumococc
vaccin cover valent could threaten
prevnar cover two fewer valent howev
overal view uncertainti low base
low volatil cash flow divers product portfolio
inelast demand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
capit research manag compani
new york mellon corp
share
fund
share
fund
rate stewardship standard
compani made mani poor capital-alloc decis
past decad current manag team
appear focus significantli better use cash
includ share buyback dividend also decis
sell nutrit anim healthcar busi
appear creat valu sharehold
front acquisit hospira strengthen
moat establish drug segment price look
reason howev high price paid mediv
fail attempt acquir astrazeneca allergan
concern
surpris move name longtim veteran
ian read ceo post abruptli replac jeffrey kindler
believ earlier-than-anticip departur kindler
larg due person reason believ
transit rais red flag read bring
year experi post
recent charg compani biopharmaceut
busi ceo read brought stamp post
signal strong willing cut buy back
share believ read leadership bring chang
need increas compani growth potenti
report side account transpar ideal larg
financi distort caus frequent
acquisit reconcili gener accept
account practic result adjust result
complex dilut clariti earn statement
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
report steadi result announc
divest gener busi jul
expect major chang fair valu
estim second-quart result larg
met expect announc divest
firm off-pat drug group upjohn
divest gener busi strengthen
competit posit wide moat exit
busi carri drug low price power focu
innov core drug
divest upjohn close total sale enabl
acceler growth rate major
upjohn drug face increas gener competit
expect group post averag annual declin
next five year divest gener group
remain innov busi line post
five-year compound annual growth rate close
almost basi point combin entiti growth
outlook addit net close billion
cash divestitur go debt
repay set strong balanc sheet
make addit acquisit drive growth
turn quarter post oper sale
growth recent launch drug offset gener
competit sever older drug expect gener
pressur increas gener competit
intensifi howev
divest upjohn busi includ lyrica
growth prospect improv
expect continu growth sever larg drug includ
cancer drug ibranc potenti expand indic
inferior drug warfarin prevnar platform
expand vaccin cover seven addit valent
look pipelin recent launch
drug well posit drive futur growth
vyndaqel immunolog drug abrocitinib array
cancer drug also well posit late-
stage drug target immunolog oncolog rare
diseas area strong price power complet
review pipelin current market portfolio
secur
innov counter price gener
headwind acceler
pfizer announc strateg sound acquisit
array reason price jun
announc acquisit array add sever well-
posit drug expect major chang
fair valu estim continu view
market pipelin drug focu oncolog
rare diseas price power typic strong
overal ad array drug portfolio
reinforc wide moat
believ key asset deal array approv
cancer drug braftovi mektovi drug combin
alreadi gain approv braf mutat melanoma
close melanoma patient base excel
clinic data drug lost first-mov
advantag drug similar mechan action
novarti roch clinic data array drug
look better cross-trial comparison
scientif appropri give signal
comparison addit braftovi mektovi face
competit merck bristol drug
melanoma importantli outsid melanoma braftovi-
mektovi combin show excel data braf
mutat colorect cancer colorect cancer
set potenti first-mov advantag area
also drug shown compel data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
colorect cancer beyond braftovi mektovi believ
strong royalti stream sever outlicens drug
rare cardiovascular diseas also provid
choic current entrench posit along
strong patent might preclud merck launch
vaccin strengthen long-term prospect
vaccin franchis
turn pipelin well posit launch
new drug off-set diminish patent loss headwind
next five year patent loss lyrica
slow growth face fewer patent loss
subsequ year also pipelin strength
improv last three year set acceler
growth next sever year
pipelin project blockbust sale rare-diseas
drug tafamidi two jak immunolog drug
increasingli strong drug
target cancer immunolog rare diseas metabol
area howev recent long-term data pain drug
safeti expect slightli reduc probabl
approv partner lilli discuss potenti next
step regulatori agenc drug
complet review pipelin current market
remain secur innov counter price gener
headwind acceler
acquisit cost array billion enterpris
valu look appropri price rel
potenti cash flow expect fund deal
cash hand debt look easili obtain
current debt-friendli market expect deal close
second half line guidanc
steadi product post strong
report first-quart result larg line
expect expect chang fair
valu estim continu view under-valued
invest commun like appreci
solid portfolio current market drug reinforc
wide moat rate
quarter total sale increas strong growth
major recent launch drug offset
larg flat growth matur product divis
cardiovascular drug eliqui cancer drug ibranc
pneumococc vaccin prevnar post double-digit
growth expect continu robust growth eliqui
ibranc take share older less effect
drug expect mild growth prevnar go
forward project major share loss merck
competit pipelin vaccin provid close
coverag pneumococc strain
develop next-gener vaccin prevnar
close coverag prevnar expect
increas coverag make prevnar best
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
